Thursday, 30 July 2009
Tuesday, 28 July 2009
SAFC orders boosted by H1N1
Sales at Sigma-Aldrich's fine chemicals business, SAFC, declined 14% in Q2 2009. The company said sales improved in Q2 against Q1, but were weak compared to 2008. The SAFC saw increased booked orders for future delivery, rising 19% in Q2 to an all-time high, some of which are for H1N1 related products. The company expects SAFC to make a modest overall contribution to its low single-digit organic growth expectations for 2009.
Seeking Alpha
Albemarle sees fine chemicals income decline 80%
Albemarle's Fine Chemicals business saw sales decline 32% to $104m in Q2 2009, and income decline from $24.5m to $5.2m. The company attributed the declines to reduced sales and production volumes but is encouraged by a strong new product pipeline for the second half of the year.
RTT
Thursday, 23 July 2009
Cambridge Major to open new API facility
Cambridge Major Laboratories will inaugurate its new API plant in Gemantown, WI, next week. The facility, which will become operational during August, will allow the company to provide large scale production for its customers.
Milwaukee and Southeastern Wisconsin Business News
Wednesday, 22 July 2009
Tuesday, 21 July 2009
Fine chems first quarter positive for Johnson Matthey
Johnson Matthey says its Fine Chemicals Division was well ahead of last year in the first quarter. The company said demand has been less affected by the recession than some other business units and it has generated income from the generic version of Adderal XR, launched in April.
Easy Bourse
Lonza consolidates custom manufacturing operations
Lonza has brought its fine chemical and biopharmaceutical custom manufacturing operations together into a single business unit. The Lonza Custom Manufacturing unit is designed to help the company's sales and marketing activities.
Easy Bourse
Sunday, 19 July 2009
Senate committee vote on biosimilars
The US Senate Health, Education, Labor and Pensions Committee has approved an amendment that would provide innovative biologic drugs with 12 years protection from competition by biosimilar products.
Wall Street Journal
Sunday, 12 July 2009
Thursday, 9 July 2009
Tuesday, 7 July 2009
Sunday, 5 July 2009
Buyer sought for Isochem
Groupe SNPE is seeking a buyer for its Isochem fine chemicals business. SNPE expects the sale to be completed within six to eight months.
SNPE
Wednesday, 1 July 2009
Lonza in contract dispute with Altus
Altus Pharmaceuticals has terminated a supply agreement with Lonza citing an alleged breach in the manufacture and supply of key ingredients. The move follows Lonza suing Altus over accusations that the contract was terminated in violation of certain covenants.
Boston Business Journal
